The first study, which directly compared the immune responses of the London-Pfizer and AstraZeneca COVID-19 vaccines, found strong and broadly similar antibody responses over the age of 80 after the first dose of either shot. Those said on Wednesday.
A British study found that a key component of the immune system, known as T cells, was more responsive in people vaccinated with the AstraZeneca / Oxford University vaccine than in people vaccinated with the Pfizer / Bio-N-Tech vaccine. I also understand.
The scientists behind the study, which analyzed blood samples from 165 British people between the ages of 80 and 99 who received the first dose of the COVID-19 vaccine, said the findings deserve further investigation.
Antibodies can block the ability of coronavirus to invade human cells, but T cells can act as broader protection by attacking and killing virus-infected cells.
“These vaccines are equally effective in inducing an antibody response in the vast majority of people. [in this study]Paul Moss, a professor of hematology at the University of Birmingham in the United Kingdom, who co-led the study, said:
“Both vaccines are good,” he told a briefing about the findings.
Researchers also found that previous infections with SARS-CoV-2 “significantly enhanced” the immune response. Evidence of previous spontaneous infections was found in 8 donors across the 165 cohort, according to the report, and was associated with 691- and 4-fold increases in humoral and cell-mediated immune responses.
The study was published online Lancet preprint Before being peer reviewed. Major antibodies were present and similar levels in 93% of 76 study participants who received Pfizer’s single COVID-19 vaccination and 87% of 89 participants who received AstraZeneca injections. It turned out to be.
Helen Parry, a clinical lecturer at the University of Birmingham, who co-led the study, said the test also showed that the majority of people who received the AstraZeneca vaccine showed a detectable T-cell response.
This finding suggests that antibodies that block coronavirus attachment to human cells may not be the only important component of immunity, and that T cells may also have important protections. The role added to other new evidence from the COVID-19 study.
“We need to do more research to understand what this difference in T cell response means,” says Parry.
About half of the UK’s population receives at least one dose of the COVID-19 vaccine, one of the highest rates in the world. The majority have been shot by Pfizer or AstraZeneca.